ENDRA Life Sciences to Participate in Two Upcoming Investment Conferences

Rhea-AI Summary

ENDRA Life Sciences (NASDAQ:NDRA) will participate in two virtual investment conferences. The first is the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, where a recorded presentation will be available on demand starting September 13. The second is the Oppenheimer Fall Healthcare Life Sciences & Med Tech Summit on September 20-23, with a live presentation on September 21 at 1:15pm ET. ENDRA specializes in Thermo Acoustic Enhanced UltraSound (TAEUS), a technology aimed at visualizing tissue at a fraction of MRI costs, initially focusing on liver health diagnostics.

ANN ARBOR, MI / ACCESSWIRE / September 7, 2021 / ENDRA Life Sciences Inc. (NASDAQ:NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS^®), announces that management will participate in two upcoming virtual investment conferences.

• H.C. Wainwright 23^rd Annual Global Investment Conference, September 13 - 15, 2021. Management will deliver a company presentation and will be available for one-on-one meetings with investors in a virtual format. The recorded presentation will be available on demand beginning Monday, September 13^th on the Investors section of ENDRA's website and here.
• Oppenheimer Fall Healthcare Life Sciences & Med Tech Summit, September 20 - 23, 2021. Management will deliver a company presentation on Tuesday, September 21^st at 1:15pm Eastern Time and will be available for one-on-one meetings in a virtual format.

About ENDRA Life Sciences Inc.

ENDRA Life Sciences is the pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS^®), a ground-breaking technology being developed to visualize tissue like MRI, but at 1/50th the cost and at the point of patient care. TAEUS^® is designed to work in concert with 400,000 cart-based ultrasound systems in use globally today. TAEUS^® is initially focused on the measurement of fat in the liver as a means to assess and monitor Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH), chronic liver conditions that affect over one billion people globally, and for which there are no practical diagnostic tools. Beyond the liver, ENDRA is exploring several other clinical applications of TAEUS^®, including visualization of tissue temperature during energy-based surgical procedures. For more information, please visit www.endrainc.com.

Company Contact:

Irina Pestrikova
Senior Director, Finance
investors@endrainc.com
www.endrainc.com

Investor Relations Contact:

Yvonne Briggs
LHA Investor Relations
(310) 691-7100
YBriggs@lhai.com

SOURCE: ENDRA Life Sciences Inc.

View source version on accesswire.com:
https://www.accesswire.com/662253/ENDRA-Life-Sciences-to-Participate-in-Two-Upcoming-Investment-Conferences

FAQ

What are the dates for the H.C. Wainwright investment conference for ENDRA Life Sciences (NDRA)?

The H.C. Wainwright 23rd Annual Global Investment Conference will be held from September 13-15, 2021.

When will ENDRA Life Sciences present at the Oppenheimer Fall Healthcare Life Sciences & Med Tech Summit?

ENDRA Life Sciences will present on September 21, 2021, at 1:15pm Eastern Time.

What technology does ENDRA Life Sciences (NDRA) specialize in?

ENDRA specializes in Thermo Acoustic Enhanced UltraSound (TAEUS), a technology for tissue visualization at lower costs than MRI.

What is the focus of ENDRA's TAEUS technology?

TAEUS initially focuses on measuring fat in the liver to assess Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH).